Overview

Imaging Depression in Parkinson's Disease

Status:
RECRUITING

Trial end date:
2029-12-01

Target enrollment:

Participant gender:

Summary

The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the ages of 40 and 80, who are experiencing symptoms of depression.

Phase:

PHASE2

Details

Lead Sponsor:

Yale University

Collaborator:

National Institute of Neurological Disorders and Stroke (NINDS)

Treatments:

1-((3-(methylpyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one
Ketamine